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1. INTRODUCTION  
 
              In our Time lung cancer incidence increase. With new drugs the treatments 
possibilities are higher and with this the side effects of chemotherapy also increase.  
High-dose Cisplatin (Cp) – based combination chemotherapy regimens are used as 
front-line treatments of small cell (SCLC) and non small cell lung cancer (NSCLC). 
The therapeutic effects of Cp are significantly improved by dose escalation, but in this 
time the nephrotoxicity is also escalated. The modality to prevent this now is only 
hydration. Different hydration protocols were developed, but one certain effective it 
isn’t. The medical studies showed, that age, female sex, smoking decreased the Cp- 
induced renal function damage. They are no data about influence of comorbidities as, 
for example, hypertension (HT), ischemic heart disease (CD) and diabetes mellitus 
(DM). Our patients are older, with this they comorbidities incidence increased. This  
can have influence for Cp-induced nephrtoxicity. This patients could have 
nephrosclerosis sooner they serum creatinin level [creat] increased.                
                Vitamin E and C, selen, melatonin, erythropoietin, amifostine, etc. can  
protect kidneys from Cp nephrotoxicity in animals. Amifostine, with approbation from 
Food and Drug Administration (FDA) to prevent Cp nephrotoxicity, is not used for 
expensiveness. CV 247 (CV) is composed of manganese and cupper gluconates, sodium 
salicylate and ascorbic acid, which components are known in animal experiences Cp 
nephrotoxicities preventive substance, could have nephroprotective effect.  
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2.  OBJECTIVES  
 
1. Could pre- Cp [creat] predict Cp nephrotoxicity?  
2. Can predict calculated isotopic GFR before Cp treatment the Cp-induced  
nephrotoxicity?   
3. Have influence the patient’s comorbidities for incidence of Cp nephrotoxicity?  
4. Is CV protective against Cp nephrotoxicy?  
 
3. METHODS  
 
3.1. Prospective clinical study 
             The Pulmo-Oncology Unit of  Dept. of Pulmonology at Semmelweis University 
(Budapest, Hungary) treats 250-300 nonsmall and small cell lung cancer patients 
annually. Since Cp-induced reversible or persistent uraemia was estimated to occur in  
30% of our patients, in order to investigate whether GFR was already reduced before Cp 
treatment when [creat] was still normal, in prospective study, we measured GFR by 
clearance of 
99m
Tc-DTPA- diethylene thiamine pentaacetic acid- (Izotóp Intézet Kft, 
Budapest, Hungary) in 38 stage IIIB-IV lung cancer patients with normal [creat] 
scheduled for Cp-based chemotherapy. 
99m
Tc-DTPA clearance was measured after 
administration of 40 MBq i.v. at the Dept. of Radiology- and Oncotherapy of 
Semmelweis University by L. Duffek. Patients were then grouped according to their 
highest post-Cp [creat] either below (n=15) or above (n=23) the upper limit of the 
reference range (>106 µmol·L-1) any time during their chemotherapy (2-4 cycles). Cp 
was administrated at 75mg·m-2 i.v. (Teva Hungary, Budapest) in each cycle. Cp 
infusions were ≥ 21 days part.  
 
3.2. Retrospective clinical study   
              We retrospectively analysed records of patients (n=242) suffering from stage 
IIIA-IV nonsmall or small cell lung cancer and receiving chemotherapy between 
January and December 2006. Based on initial evaluation of the 242 patients, three major 
subgroups were formed according the absence or presence of the comorbidities CD 
and/or DMIH. The NC subgroup had no hypertension, ischemic heart disease or 
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diabetes mellitus. The CD subgroup was formed based on presence of long-term, 
medically controlled hypertension and ischaemic heart disease (together cardiovascular 
disease; n=110), and the DMIH subgroup was based on the combinated presence of 
diabetes mellitus and ischaemic heart disease without hypertension (n=52). The 
diagnosis of chronic arterial hypertension was based on history and the use of 
antihypertensive medications. Ischaemic heart disease was diagnosed based on history, 
ECG abnormalities and previous treatment with coronary vasodilatators, platelet 
aggregation inhibitors or percutaneous transluminal coronary angioplasty. None of the 
CD patients suffered from uncontrolled hypertension, angina pectoris, acute myocardial 
infarction or cardiac decompensation, or from any other acute or severe cardiovascular 
comorbidity that could have contraindicated chemotherapy with high-dose Cp. Diabetes 
mellitus was diagnosed based on history, treatment with insulin (n=5) or oral 
antidiabetic treatment (n=47) and higher than normal fasting serum glucose 
concentration. None of the DMIH patients suffered from uncontrolled hyperglycaemia 
or had symptoms of major complications of diabetes. Urinary protein test showed 
opalescence (≥1 g·day−1) in two patients and slight opalescence (0.5–1.0 g·day−1) in two 
other patients; the majority had negative (<0.5 g·day−1) results. Patients received several 
subsequent combined chemotherapy courses, always containing high-dose Cp (75 
mg·m−2 i.v.), and each pre- and the highest post-Cp [creat] concentration values were 
recorded. Cp-induced persistent uraemia (which indicates Cp nephrotoxicity) was a 
frequent cause of exclusion from further Cp treatment. The number of these patients 
was compared between the three groups. Clinical data, such as age, sex, chronic 
comorbidity, blood pressure and stage of lung cancer were collected. With regard to 
laboratory data, serum glucose and [creat] concentrations were analysed. [creat] was 
determined based on the modified Jaffe two-point kinetic reaction using commercially 
available test from Dialab (Wiener Neudorf, Austria). Ccreat (eGFR) was calculated 
according the Cockcroft–Gault equation. This calculation was selected because the 
mean age of our patients was <65 yers.  
               Cp was provided  by Teva Hungary (Budapest, Hungary) and EBEWE Pharma 
(Unterach, Austria) and administered at a dose of 75 mg·m−2. One of three additional 
chemotherapeutic agents was given in combination with Cp: gemcitabine (gem, 1,250 
mg·m−2; Eli Lilly, Houten, the Netherlands), etoposide (etop, 3×120 mg·m−2) and 
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paclitaxel (pac, 175 mg·m−2; both Bristol-Myers Squibb, Princeton, NJ, USA). 
Neutropenia was treated with granulocyte colony-stimulating factor (filgrastim, 48 mU; 
Amgen, Breda, the Netherlands), severe thrombocytopenia with platelet transfusion, and 
anaemia with erythropoietin (Epoetin alfa, 40,000 IU·week−1; Janssen-Cilag, Centocor, 
Leiden, the Netherlands) and/or transfusion as indicated. Patients received 
antinociceptive and antiemetic drugs, bisphosphonate, methylprednisolone and other 
symptom relievers, as needed.  
              An i.v. infusion of 500 mL 0.9% NaCl was followed by either gemcitabine, 
taxol or etoposide in a further 500 mL saline. After a third 500-mL saline infusion, Cp 
was infused again in 500 mL. In our hands, infusion of 500 mL usually takes 20–30 
min. Following Cp, the fifth 500 mL saline was infused (total volume of saline 2.500 
mL within ∼2.5 h) and the infusion treatment was ended with 100 mL 20% mannitol 
(Baxter, Deerfield, IL, USA) i.v. 
                 Data are presented as means±SEM. Statistical analysis was performed using 
GraphPad software (Graph Pad Prism 5.0; Graph Pad Software, Inc., San Diego, CA, 
USA) using Fisher’s exact test, the Chi-squared test and t-tests (paired and unpaired) as 
appropriate. One-or two-way ANOVA and the Kruskal–Wallis test was used to 
compared more than two groups. Normally distributed data were analysed by ANOVA 
and non-Gaussian distributed or nonparametric values were analysed by Kruskal–Wallis 
test. After one-way ANOVA, if significant difference (p<0.05) was found, the 
Newman–Keuls multiple comparison post hoc test was used for further analysis. After 
two-way ANOVA, a Bonferroni post-test was used. After the Kruskal–Wallis test, 
Dunn’s multiple comparison post hoc test was performed. The applied tests are 
described in the table and figure legends.  
 
3.3. Animal experience   
               The study was conducted on 40 male, 8-week old Wistar rats weighing 175-
190 g. The animals were randomly divided into 4 groups (n=10/group). They were kept 
individually under standard conventional conditions according to European Council 
Directive 123. The study conformed to the Declaration of Helsinki guidelines and was 
approved by the local Animal Ethic Committee. Cp (10 mg in 20 ml) was obtained from 
TEVA, Israel. The composition of  CV247 (Pharmaserve Ltd, Manchester UK) was the 
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following: 40 mg ascorbic acid, 2 mg manganese gluconate (unique selling proposition- 
USP), 2 mg copper gluconate and 35 mg sodium salicylate per millilitre solution. The 
dose given was 2 x 120 mg·kg-1·day-1 vitamin C (Vit. C), 2 x 105 mg·kg-1·day-1 sodium 
salicylate, 2x6 mg·kg-1·day-1 copper gluconate and 2.6 mg·kg-1·day-1 manganese 
gluconate. Methyl cellulose mucilage (Dow Chemicals, Midland, MI, USA) was 
prepared in distilled water (1 %). 
              Control group (C) received 1% methyl cellulose at 10 ml·kg body weight-1, per 
oral (p.o.) by gastric gavage twice daily for 14 days. Another group of rats received 
CV247 at 3 ml·kg body weight-1, p.o. twice daily for 14 days (CV). Two groups were 
intraperitoneally injected with a single dose of Cp at 6.5 mg·kg body weight-1. Cp was 
suspended in 10 ml·kg-1 1% methyl cellulose. One of the groups injected with Cp was 
subsequently treated with vehicle (C) or CV at 3 ml·kg body weight-1, p.o. twice daily 
for 14 days (CV+Cp). All rats were weighed and food and water consumptions were 
also measured daily. On day 12 were 1.5 ml blood samples taken from all rats by retro- 
orbital puncture under isoflurane anaesthesia after a 20-hour food deprivation. The 
blood was anticoagulated with citrate and centrifuged twice at 2500 r·min-1 for 10 min 
at +4 C to obtain plasma. (creat) and blood urea nitrogen (BUN) were determined from 
the plasma by colorimetric tests using commercially available kits. Rats were terminally 
anaesthetised with an overdose of pentobarbital on day 14. Blood was collected by 
aortic puncture and one kidney from each animal was removed and weighed. Kidneys 
were fixed in 8% buffered formalin (pH 7.4), paraffin sections were prepared and 
stained with haematoxylin–eosin. Renal histological changes were blindly evaluated 
using a 5-grade severity scale (0 =no change; 1= minimal changes; 2=mild changes; 
3=moderate changes; 4=severe changes). The cyclooxygenase-2 (COX-2) 
immunohistochemistry was done using a mouse monoclonal COX-2 primary antibody 
(Novocastra, UK) at 1:100 dilution. The secondary antibody was a peroxidase-
conjugated mouse/rabbit polymer (Dako Real™ Envision™ /HRP, Rabbit/Mouse). 
Diaminobenzidine was used for visualisation. 
              Means±SD are given throughout. The statistical comparisons were performed 
by two-way repeated measures ANOVA with Bonferroni post hoc test or Mann-
Whitney U test using GraphPad Prism 5 for Windows, or by two-way ANOVA using 
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the SPSS 17 for Windows, when appropriate. The level of significance was set at 
p<0.05. 
 
4. RESULTS  
 
4.1. Clinical studies results   
 
4.1.1. Results of prospective clinical study  
             Out of the 38 lung cancer patients, 23 patients responded with pathologically 
increased [creat] after Cp (table I), although pre-treatment [creat] values were normal in 
both groups. Pre-treatment GFR, as measured by clearance of 
99m
Tc-DPTA, was 
significantly reduced by ~25% in those lung cancer patients with azotaemia who 
responded to 2-4 cycles of Cp treatment. 
 
Table I. Pre-Cp glomerular filtration rate (GFR) of 38 initially non uraemic lung 
cancer patients  
Subgroup  
pre-Cp 
creat  
post-Cp 
creat  
pre-Cp GFR 
(mL·min-1·m-2) 
Age  
(yrs) 
Males/ 
females 
 ( mol.L
-1
) 
Cp nephrot. 
(n=23) 
79 4
1
 167 12
1
 73.51 4
1
 63.6 1.5
ns1
 13/10
ns2
 
No Cp nephrot. 
(n=15) 
68 3 87 4 98.6 4.6 60.5 2.8 8/7 
: p 0.05, not significant (ns): p 0.05 compared with „No Cp nephrotoxicity” group; 
1: unpaired t-test; 2: Fischer’s exact test  
 
4.1.2. Results of retrospective clinical study   
              Table II contain all patient’s clinical data and in table III we can see patients 
[creat] values before and after Cp treatments.   
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Table II. Clinical data of patients recevieving high-dose Cp for lung cancer  
 NC(n=80) CD (n=110) DMIH(n=52) 
Age (yrs) 56 1 60 1  62 1  
Males/females (n) 45/35 66/44
ns
 33/19
ns
 
BMI (kg·m-2) 24.3 0.4 25.4 0.4ns 25.4 0.6ns 
Dose of Cp per treatment (mg) 123 2 126 2
ns
 124 4
ns
 
Total dose of  Cp (mg) 375 22 399 22
ns
 392 43
ns
 
Mean number of cycles (n) 3.1 0.2 3.2 0.2
ns
 3.2 0.3
ns
 
Cp+gem/etop/tax(patients 
number) 
38/41/1 52/55/3
ns
 25/24/3
ns
 
Systolic/diastolic blood pressure 
(mmHg) 
132 2/81 1 134 2/81 1
ns
 137 3/84 2
ns
 
Cardiac frequency beats (beats 
·min-1) 
81 1 82 1
ns
 86 2
ns
 
: p 0.05, ns: p 0.05 compared with NC  
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Table III.[creat] in lung cancer patients receiving 1-4 cycles of high-dose Cp  
Cp cycle  NC Cd DMIH 
1st Patients number 
[creat] µmol·L-1 
Pre-Cp 
Post-Cp 
80 
 
77 1 
82 2  
110 
 
78 1
 ns
 
95 4 † 
52 
 
77 3
 ns
 
94 4 † 
2 2nd Patients number 
[creat] µmol·L-1 
Pre-Cp 
Post-Cp 
68 
 
80 2 
88 4  
96 
 
86 2
 ns
 
105 5 † 
49 
 
82 3
 ns
 
110 6 † 
3rd Patients number 
[creat] µmol·L-1 
Pre-Cp 
Post-Cp 
42 
 
85 3 
91 5  
64 
 
91 3
ns
 
113 5 † 
31 
 
83 4ns
 ns
 
117 9 † 
 4th Patients number 
[creat] µmol·L-1 
Pre-Cp 
Post-Cp 
35 
 
84 4 
93 5  
47 
 
95 3
 ns
 
117 8 † 
30 
 
89 3
 ns
 
121 5 † 
: p 0.05 compared with pre-Cp (paired t-test); not significant (ns): p 0.05; 
 †: p 0.05 compared with NC (two-way ANOVA with Bonferroni after test).              
                Pre- treatments [creat] are not increased. After every treatment [creat] 
increased significant, what shows Cp nephrotoxicity. In NC group [creat] was every 
time physiologic, but in other two groups were increased. Before the new cycles of 
chemotherapy [creat] level decreased in normal range, these need to continue Cp 
therapy.  DMIH patients’ kidney pre- treatments were not intact, that is responsible for 
this high number of post-Cp azotaemia. Table III. shows, that this comorbidities 
predispose patients to Cp nephrotoxocity. They incidence can’t predict by pre treatment 
[creat] values. 
                   Cp induced azotaemia was in NC group 7.5, in CD group 20.9 (p<0.05 
compared with NC) and in DMIH group 30.8% (p<0.01 compared with NC) (Figure 1.)  
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Figure 1. Frequency of nephrotoxicity (dark) and nephrotoxicity-related drop-out 
from futher Cp treatment (bright) in lung cancer patients receiving 1-4 cycles of 
high-dose Cp and suffering from hypertension and ischaemic heart disease (CD), 
or diabetes mellitus and ischaemic heart disease (DMIH), or being free from these 
severe comorbidities (NC). 
*: p 0.05 compared with NC, **: p 0.01 compared with NC; #: p 0.01 compared with 
CD (two-tailed difference tests). 
               Calculated GFR before Cp treatments where significant higher in that group, 
which later don’t have azotaemia. That show, calculated GFR could be predictive for 
Cp nephrotoxicity. This reproduce table I. results.   
 
Figure 2. Summary of pre-Cp treatment calculated GFR values together in 3 
patients groups (NC, CD, DMIH)  
Difference was calculated with Mann Whitney test.*: p<0.01 Cp releated azotaemia 
with no azotaemia.  
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Figure 3. Pre- (dark) and post- (bright) Cp estimated glomerular filtration rate 
(eGFR) values during the 1st-4th cycles of high-dose Cp treatments in lung cancer 
patients suffering from no comorbidity (NC), controlled hypertension and 
ischaemic heart disease (CD), or controlled diabetes mellitus and ischemic heart 
disease (DMIH).   
Numbers above the bars represent the number of patients. *:p<0.05 compared with pre-
Cp (paired t-test); not significant (ns) compared with NC (two-way ANOVA with 
Bonferroni after test); #:p<0.05 compared with NC (two-way ANOVA with  Bonferroni 
after test). 
             When the estimated glomerular filtration rate (eGFR) before Cp therapy was 
lower or between 60-70 mL·min-1m-2, the incidence of post-Cp nephrotoxicity was very 
high.  
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4.2. Animal experience  
4.2.1.Body weight   
 
Figure 4. Cp dicreased significant body weight of rats from 2nd day.  
               Body weight of rats steadily increased in control group from 171±8 g to 
234±15 g  over a study period of 14 days with a drop on day 11 after the overnight food 
deprivation before blood sampling. In comparison with baseline values, Cp caused a 
5.5% peak body weight loss (p<0.001) on day 3 after treatment. CV treatment did not 
influenced body weight in comparison with C and Cp groups. 
               
4.2.2. Water consumption  
               CV consistently increased water consumption in comparison with C group 
(Figure 5) which was statistically significant on days 8, 9 and 11 (p<0.05 all). Cp 
caused short, non-significant decrease in water consumption on day 2 after its 
administration (daily -5- -10 mL). Therefore, from day 4, rats in Cp and CV+Cp groups 
drank significantly more water than rats in group C. Co-administration of CV to Cp did 
not alter water consumption in comparison with the group treated with Cp only. In 
comparison with C group animals with Cp consume more water. CV alone increased 
water consumption.  
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Figure 5. From 5 day (*) water consumption was significantly increased in groups 
treated with Cp and CV+Cp in comparison to the C group.  The open circles show 
that on days 8, 9 and 11 water consumption was significantly increased in the 
group treated with CV in comparison to the group treated with vehicle. 
 The statistical analysis was performed by two-way ANOVA with Bonferroni after test. 
 
4.2.3. Renal function   
               [creat] and [BUN] values were within physiological limit in groups C and CV. 
([creat]: 17.0- 22.5 μmol·L-1, [BUN]: 6.63- 10.48 mmol·L-1). Cp increased both 
significant (p<0.01) in day 12 taked blood samples. CV did not alter (p>0.05 both) these 
effects of Cp on renal function (Figure 6 and 7).     
                                  
Figure 6. CV did not alter Cp caused azotaemia. (two-way ANOVA)  
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Figure 7. CV have no effect of [BUN]. (two-way ANOVA)  
 
4.2.4. Kidney histology and immunohistochemistry 
            
Figure 8. CV have nephroprotective effect. (haematoxylin-eosin staining). 
A.C:normal histology; B+E.Cp:severe degree of tubulointerstitial abnormality 
(3.67±0.50);  C.CV: normal histology; D+F.CV+Cp: significantly less severe alterations 
we in group Cp (2.67±0.71; p<0.01) E and F higher magnification of sections.  
Abnormalities were statistifically compared by two-way ANOVA.    
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             No histological changes were seen in kidneys in groups C and CV; that show 
CV have no kidney nephrotoxicity. Blind assessment demonstrated a significant 
(p<0.01) reduction in the mean of histological kidney injury from 3.67±0.50 in Cp to 
2.67±0.71 in CV+Cp group. 
             Immunohistochemistry related a moderate degree of focal COX-2 activity in the 
cytoplasm of tubular epithelium in the interstitial space and in the walls of major blood 
vessels (C:1,20±0.42, CV:1,0±0,0). Blind assessment of COX-2 immunoreactivity 
markedly increased in the groups treated with Cp and CV+Cp. Treatment with CV did 
not alter COX-2 immunoreactivity in comparison C but slightly  (Cp:3.00±0.71 versus 
CV+Cp:2.44±0.53, p=0.097). Our study showed that CV could prevent Cp 
nephrotoxicity.  
 
Figure 9. Cp effect and CV protective effect on COX-2 immunohistochemistry in 
renal cortex.     
A.C: mild activity in the interstitium and tubular epithelium; B+E. Cp increased COX-2 
activity int he damaged areas of the kidney (3.67±0.50); C.CV: mild activity in the 
interstitium and tubular epithelium;  D+F. CV+Cp: Cp effect is significant decreased by 
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CV (2.67±0.71; p<0.01) E and F higher magnification of sections. Abnormalities were 
statistifically compared by Mann Whitney test.   
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5. CONCLUSIONS  
 
1.The risk of nephrotoxicity should always be evaluated based on eGFR. 
2.Lower eGFR (60-80 ml·perc-1) with normal [creat] and [BUN] before Cp therapies 
predict Cp nephrotoxicity.   
3.Coexisting CD or DMIH, because narrow the tolerance of the kidneys to Cp, 
increased the incidence of Cp nephrotoxicity.  
4. CV 247 can attenuate Cp caused nephrotoxicity.    
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